Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2553 • ACR Convergence 2023
Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
Yanjie Hao¹, Dylan Hansen², Rangi Kandane-Rathnayake³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Jiacai Cho⁶, Aisha Lateef⁶, Laniyati Hamijoyo⁷, Shue-Fen Luo⁸, Yeong-Jian J Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Zhanguo Li¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Sang-Cheol Bae¹⁸, Fiona Goldblatt¹⁹, Sean O’Neill²⁰, Kristine Ng²¹, Annie Law²², BMDB Basnayake²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Cherica Tee²⁶, Michael Tee²⁶, Yoshiya Tanaka²⁷, Chak Sing Lau²⁸, Vera Golder³, Alberta Hoi²⁹, Eric Morand³⁰, Shereen Oon³¹ and Mandana Nikpour³², ¹The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹²University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁶Keio University School of Medicine, Tokyo, Japan, ¹⁷Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁸Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁹Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²⁰Department of Medicine, University of New South Wales, Kensington, Australia, ²¹Waitemata DHB, Auckland, New Zealand, ²²Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²³Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Middlemore Hospital, Auckland, New Zealand, ²⁶University of the Philippines, Manila, Philippines, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²⁹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³⁰Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³¹University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ³²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: There is increasing interest in adopting the principle of treating to target (T2T) in systemic lupus erythematosus (SLE). Remission and low disease activity states…
Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Mucong Li¹, Chaiquan Li², Mengzhuo Cao³, Ke Lu², Chanyuan Wu³, Jiuliang zhao¹, Qian Wang⁴, Xinping Tian¹, Xun Tang², Mengtao Li¹, xiaofeng Zeng⁴ and Pei Gao², ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
Abstract Number: 0184 • ACR Convergence 2023
Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE
Donavon Sandoval-Heglund¹, Eric Roberts², Joonsuk Park², Maria Dall'Era², Kamil Barbour³, Cristina Lanata⁴, Kurt Greenlund³, Caroline Gordon⁵, Patti Katz⁶ and Jinoos Yazdany², ¹University of California San Francisco School of Medicine, La Quinta, CA, ²University of California San Francisco, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴National Human Genome Research Institute, Washington, DC, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶University of California San Francisco, San Rafael, CA
Background/Purpose: Lower socioeconomic status is associated with greater disease activity and mortality in systemic lupus erythematosus (SLE); however, mechanisms driving this are yet to be…
Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Hiromi Shimada¹, Rina Mino², Risa Wakiya³, Shusaku Nakashima³, Taichi Miyagi⁴, Yusuke Ushio⁵, Koichi Sugihara⁶, Mao Mizusaki³, Kanako Chujo⁷, Ryoko Kagawa⁵, Hayamasa Yamaguchi⁵, Tomohiro Kameda³ and Hiroaki Dobashi³, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…
Abstract Number: 0555 • ACR Convergence 2023
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
Neha Gupta¹, Sarah Ford², Lane Scheiber², Tangada Rao² and Abhishek Nandan², ¹Virginia Commonwealth University Health Systems, Richmond, VA, ²Virginia Commonwealth University Health Systems; Veterans Affairs Medical Center, Richmond, VA
Background/Purpose: The management of a positive anti-nuclear antibody (ANA) is one of the most common consultations in rheumatology outpatient practice. The prevalence of a positive…
Abstract Number: 0572 • ACR Convergence 2023
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
Erdem Gurel¹, Suzan Cinar², Ozge Hurdogan³, Yasemin Ozluk³, Isin Kilicaslan⁴, Sibel Varelci¹, Safak Mirioglu⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Lale Ocal¹, Murat Inanc⁶ and Bahar Artim-Esen⁶, ¹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ²Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbıl, Turkey, ⁵Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is…
Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Jui-En Lo¹, Pin-Chia Huang², George Tsokos³, Vasileios Kyttaris⁴, Karen Costenbader⁵ and Kevin Sheng-Kai Ma², ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴BIDMC, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…
Abstract Number: 0723 • ACR Convergence 2023
Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension
Xiaoyue Deng¹, Junyan Qian¹, Ranran Wang², JIULIANG ZHAO³, Qian Wang⁴, Tianyi Yuan², MENGTAO LI¹ and Xiaofeng Zeng⁵, ¹Peking Union Medical College Hospital, Beijing, China, ²Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Beijing Union Medical College Hospital, Beijing, China, ⁴Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious complication in SLE patients, with rapid progression and poor prognosis. In China, approximately 3% of the over…
Abstract Number: 0848 • ACR Convergence 2023
Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Kishan Majithiya¹, Komal Singh¹, Pankti Mehta², Chengappa Kavadichanda³, seema Sharma¹, Able Lawrence¹ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²King George's Medical University, Mumbai, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…
Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Yurilu Gonzalez¹ and Irene Tan², ¹Albert Einstein Medical Center, Wyncote, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…
Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…
Abstract Number: 1094 • ACR Convergence 2023
“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Christopher Macko¹, Patty Chen², Roger Santos³, Nirmala Ramalingam⁴, Nicole Tran⁵ and Sijie Zheng⁶, ¹Kaiser Oakland Internal Medicine Residency, Piedmont, CA, ²Kaiser Oakland Medical Center Department of Rheumatology, Orinda, CA, ³Kaiser East Bay Department of Pharmacy, Oakland, CA, ⁴Kaiser Oakland Medical Center Department of Graduate Medical Education, Oakland, CA, ⁵Kaiser Oakland Department of Adult and Family Medicine, Oakland, CA, ⁶Kaiser Oakland Medical Center Department of Nephrology, Oakland, CA
Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1446 • ACR Convergence 2023
Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database
Iñigo Rúa-Figueroa¹, JULIA MARTINEZ BARRIO², Norman Jiménez³, Maria Galindo-Izquierdo⁴, Esther Uriarte Isacelaya⁵, Antonio Fernandez-Nebro⁶, Jaime Calvo- Alén⁷, SARA MANRIQUE⁸, Jose Rosas⁹, Rocío Caño-Alameda¹⁰, Javier Narvaez¹¹, Inmaculada Ros¹², Elena Aurrecoechea Aguinaga¹³, Vicente Torrente-Segarra¹⁴, Clara Sanguesa Gomez¹⁵, Mercedes Freire González¹⁶, Eva Tomero Muriel¹⁷, Loreto Horcada¹⁸, Clara Moriano Morales¹⁹, Mireia Moreno²⁰, Carlota Iñíguez²¹, Ricardo Blanco²², Ana Pérez Gómez²³, Jose Luis Andreu-Sánchez²⁴, Sandra Garrote Corral²⁵, Santiago Muñoz²⁶, Gema Bonilla²⁷, Nuria Lozano Rivas²⁸, Carlos Montilla-Morales²⁹, Oihane Ibarguengoitia-Barrena³⁰, Lorena Expósito³¹, Elia Valls-Pascual³², Angela Pecondon-Español³³, Sergio Machin³⁴, Eva Salgado-Pérez³⁵, Celia Erausquin³⁶, TAREK CARLOS SALMAN MONTE³⁷, Raúl Menor-Almagro³⁸, Alejandro Muñoz³⁹, Irene Altabas Gonzalez⁴⁰, Jorge Juan Fragio⁴¹ and Jose-Maria Pego-Reigosa⁴², ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁹Hospital Marina Baixa, Alicante, Spain, ¹⁰Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ¹⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ¹⁵Severo Ochoa Hospital, Madrid, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁷Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁸Hospital de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Universitario de León, León, Spain, ²⁰Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²¹Hospital Lucus Augusti, Lugo, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²³Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Ramón y Cajal, Madrid, Spain, ²⁶Hospital Infanta Sofia, Madrid, Spain, ²⁷Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁹Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ³⁰Galdakao-Usansolo University Hospital, Bilbao, Spain, ³¹Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³²Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ³³Hospital Miguel Servet, Zaragoza, Spain, ³⁴CHUIMI, Las Palmas de Gran Canaria, Spain, ³⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ³⁶Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁷Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³⁸Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ³⁹Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ⁴⁰Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital General Universitario Valencia, Valencia, Spain, ⁴²Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The prevalence of depression and associated factors in systemic lupus erythematosus (SLE) are not well known and there are no longitudinal studies addressing this…
Abstract Number: 1463 • ACR Convergence 2023
Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus
Alexandra Lee¹, Sharon Phillips² and Leslie Crofford³, ¹Meharry Medical College, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: The purpose of this study was to investigate factors associated with objective cognitive impairment in patients diagnosed with Systemic Lupus Erythematous (SLE). Subjective complaints…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].